专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080039502A1 EP4 receptor antagonists 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US20080039502A1
公开(公告)日：2008-02-14
申请号：US11889570
申请日：2007-08-14
申请人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
发明人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
IPC分类号： A61K31/34 , A61K31/341 , A61K31/4155 , A61K31/443 , A61P25/06 , C07D231/12 , C07D231/18 , C07D307/68 , C07D307/77 , C07D405/12 , C07D413/12
CPC分类号： C07D307/54 , A61K31/34 , A61K31/341 , A61K31/4155 , A61K31/443 , C07D307/64 , C07D307/68 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(═O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.
摘要翻译：式（I）的化合物：其中：R 2是H或任选取代的C 1-4烷基; Y是 - （CH 2）n -X-，其中n是1或2，X是O，S，S（-O），S（-O ）N 2，或NR 11，其中R 0,1选自H或任选取代的C 1-4烷基，或Y是-C（-O）NR N2 - ，其中R N2选自H和任选取代的C 1-7 - 烷基或C 5-20-20芳基; R 3是与另外任选取代的C 6 -C 6芳基连接的任选取代的C 6-14芳基，其中如果两个C 6 芳基是苯环，两个环之间可能有一个氧桥，与两个环上的连接相邻; A是单键或C 1-3-3亚烷基; 和R 5是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R“N 3”和“R”N 4“独立地选自任选取代的C 1 -C 6烷基，烷基; （ⅳ）四唑-5-基。

2. 发明申请

US20070123575A1 EP4 RECEPTOR ANTAGONISTS 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US20070123575A1
公开(公告)日：2007-05-31
申请号：US11615024
申请日：2006-12-22
申请人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
发明人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Christopher Newton
IPC分类号： A61K31/41 , A61K31/34 , C07D405/02
CPC分类号： C07D307/54 , A61K31/34 , A61K31/341 , A61K31/4155 , A61K31/443 , C07D307/64 , C07D307/68 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： Compounds of formula (I): wherein: R2 is H or an optionally substituted C1-4 alkyl group; Y is either —(CH2)n—X—, where n is 1 or 2 and X is O, S, S(═O), S(═O)2, or NRN1, where RN1 is selected from H or optionally substituted C1-4 alkyl, or Y is —C(═O)NRN2—, where RN2 is selected from H, and optionally substituted C1-7 alkyl or C5-20 aryl; R3 is an optionally substituted C6 aryl group linked to a further optionally substituted C6 aryl group, wherein if both C6 aryl groups are benzene rings, there may be an oxygen bridge between the two rings, bound adjacent the link on both rings; A is a single bond or a C1-3 alkylene group; and R5 is either: (i) carboxy; (ii) a group of formula (II): ; or (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; (iv) tetrazol-5-yl.
摘要翻译：式（I）的化合物：其中：R 2是H或任选取代的C 1-4烷基; Y是 - （CH 2）n -X-，其中n是1或2，X是O，S，S（-O），S（-O ）N 2，或NR 11，其中R 0,1选自H或任选取代的C 1-4烷基，或Y是-C（-O）NR N2 - ，其中R N2选自H和任选取代的C 1-7 - 烷基或C 5-20-20芳基; R 3是与另外任选取代的C 6 -C 6芳基连接的任选取代的C 6-14芳基，其中如果两个C 6 芳基是苯环，两个环之间可能有一个氧桥，与两个环上的连接相邻; A是单键或C 1-3-3亚烷基; 和R 5是：（i）羧基; （ii）式（II）的组：或（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5-20-20芳基或NR N 3，其中R“N 3”和“R”N 4“独立地选自任选取代的C 1-4烷基 ; （ⅳ）四唑-5-基。

3. 发明申请

US20070135503A1 Furan derivatives as ep4 receptor antagonists 失效
标题翻译：呋喃衍生物作为ep4受体拮抗剂
公开(公告)号：US20070135503A1
公开(公告)日：2007-06-14
申请号：US10576095
申请日：2004-10-15
申请人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
发明人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
IPC分类号： A61K31/41 , A61K31/34 , A61K31/405 , C07D307/02
CPC分类号： C07D307/68
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii) an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
摘要翻译：式（I）化合物或其盐，溶剂合物和化学保护形式，其中R 2和R 5中的一个为：（i）H或任选地取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3， SUP>是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R 3，N 3和R 4各自独立地选自任选取代的C 1 -C 6芳基或NR N 3 N， 1-4个C 1-4烷基; 或（iv）四唑-5-基。

4. 发明申请

US20050256170A1 EP2 receptor agonists 失效
公开(公告)号：US20050256170A1
公开(公告)日：2005-11-17
申请号：US11055724
申请日：2005-02-11
申请人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Mark Ashton , Edward Boyd , Shirley Brunton
发明人： Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark , David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Mark Ashton , Edward Boyd , Shirley Brunton
IPC分类号： A61K31/4178 , A61K31/422 , A61K31/427 , A61K31/4439 , C07C233/75 , C07C233/81 , C07C235/84 , C07D213/81 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12 , C07D413/02 , C07D417/02 , C07D43/02
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisiting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O., and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2-OH; or tetrazol-5-yl.

5. 发明申请

US20050124676A1 EP4 receptor antagonists 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US20050124676A1
公开(公告)日：2005-06-09
申请号：US10964831
申请日：2004-10-15
申请人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
发明人： David Clark , Neil Harris , Garry Fenton , George Hynd , Keith Stuttle , Jonathan Sutton , Alexander Oxford , Richard Davis , Robert Coleman , Kenneth Clark
IPC分类号： A61K31/34 , A61K31/41 , C07D307/68 , C07D45/02
CPC分类号： C07D307/68
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
摘要翻译：式（I）化合物或其盐，溶剂合物和化学保护形式，其中R 2和R 5中的一个为：（i）H或任选地取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3， SUP>是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R 3，N 3和R 4各自独立地选自任选取代的C 1 -C 6芳基或NR N 3 N， 1-4个C 1-4烷基; 或（iv）四唑-5-基。

6. 发明申请

US20050176791A1 5-HT2B receptor antagonists 审中-公开
标题翻译： 5-HT2B受体拮抗剂
公开(公告)号：US20050176791A1
公开(公告)日：2005-08-11
申请号：US10640476
申请日：2003-08-14
申请人： Alexander Oxford , Richard Borman , Robert Coleman , Kenneth Clark , George Hynd , Janet Archer , Amanda Aley , Neil Harris , Andrew Goulter
发明人： Alexander Oxford , Richard Borman , Robert Coleman , Kenneth Clark , George Hynd , Janet Archer , Amanda Aley , Neil Harris , Andrew Goulter
IPC分类号： A61K31/421 , A61P9/04 , C07D263/48 , C07D413/04
CPC分类号： C07D263/48 , A61K31/421 , C07D413/04
摘要： The present invention relates to compounds which include compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein one of R1 and R4 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; and the other of R1 and R4 is an optionally substituted C9-14 aryl group; R2 and R3 are either: (i) independently selected from H, R, R′, SO2R, C(═O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5 and R6 are independently selected from H and R, where R is optionally substituted C1-4 alkyl, and R′ is optionally substituted phenyl-C1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C5-7 heterocyclic group. The compounds are useful in the treatment of conditions including conditions which can be alleviated by antagonism of a 5-HT2B receptor such as GI disorders and congestive heart failure.
摘要翻译：本发明涉及包括式I化合物或其药学上可接受的盐的化合物，其中R 1和R 4中的一个选自由以下组成的组： H和任选取代的C 1-6烷基，C 3-7环烷基，C 3-7环烷基-C 1〜 4烷基和苯基-C 1-4烷基; R 1和R 4中的另一个是任选取代的C 9-14芳基; R 2和R 3是：（i）独立地选自H，R，R'，SO 2 R，C（-O ）R，（CH 2）2 NR 6，其中n为1至4，R H和R 6独立地选自H和R，其中R是任选取代的C 1-4烷基，R'任选被取代苯基-C 1-4烷基，或（ii）与它们所连接的氮原子一起形成任选取代的C 5-7杂环基。所述化合物可用于治疗包括可通过拮抗5-HT 2B受体如GI病症和充血性心力衰竭而缓解的病症的病症。

7. 发明申请

US20050209336A1 EP2 receptor agonists 审中-公开
标题翻译： EP2受体激动剂
公开(公告)号：US20050209336A1
公开(公告)日：2005-09-22
申请号：US11019133
申请日：2004-12-22
申请人： Richard Borman , Robert Coleman , Kenneth Clark , Keith Mills , Alexander Oxford , Jian Zhang , Peter Duff
发明人： Richard Borman , Robert Coleman , Kenneth Clark , Keith Mills , Alexander Oxford , Jian Zhang , Peter Duff
IPC分类号： A61K31/192 , A61K31/557 , A61K31/5575 , C07C59/185 , C07C59/90 , C07C405/00
CPC分类号： C07C59/90 , C07C405/0025
摘要： A compound selected from one of the following: or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP2 receptor.
摘要翻译：选自以下之一的化合物或其盐，溶剂合物，化学保护形式或前药，以及其用于治疗由受体受体拮抗剂缓解的病症的用途。

8. 发明申请

US20050154031A1 5-Ht2b receptor antagonists 审中-公开
标题翻译： 5-Ht2b受体拮抗剂
公开(公告)号：US20050154031A1
公开(公告)日：2005-07-14
申请号：US10504538
申请日：2003-02-11
申请人： Alexander Oxford , Richard Borman , Robert Coleman , Kenneth Clark
发明人： Alexander Oxford , Richard Borman , Robert Coleman , Kenneth Clark
IPC分类号： C07D277/20 , A61K31/425 , A61K31/426 , A61P1/00 , A61P43/00 , C07D277/40
CPC分类号： C07D277/40 , A61K31/425
摘要： The present invention concerns compounds of formula (I): wherein R1 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; R2 and R3 are either: (i) independently selected from H, R, R′, SO2R, C(═O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5 and R6 are independently selected from H and R, where R is optionally substituted C1-4 alkyl group, and R′ is an optionally substituted phenyl-C1-4 alkyl group, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C5-7 heterocyclic group; R4 is an optionally substituted C9-14 aryl group; their use as pharmaceuticals, in particular for treating conditions alleviated by antagonism of a 5-HT2B receptor.
摘要翻译：本发明涉及式（I）的化合物：其中R 1选自H和任选取代的C 1-6烷基，C 1 -C 6烷基， 3-7环烷基，C 3-7环烷基-C 1-4烷基和苯基-C 1-4烷基 ; R 2和R 3是：（i）独立地选自H，R，R'，SO 2 R，C（-O ）R，（CH 2）2 NR 6，其中n为1至4，R H和R 6独立地选自H和R，其中R是任选取代的C 1-4烷基，R'是任选取代的苯基-C 1-4烷基，或（ii）与它们所连接的氮原子一起形成任选取代的C 5-7杂环基 ; R 4是任选取代的C 9-14芳基; 它们用作药物，特别是用于治疗通过拮抗5-HT 2B受体而减轻的病症。

9. 发明授权

US07533168B1 Autonomic grid computing mechanism 有权
标题翻译：自动网格计算机制
公开(公告)号：US07533168B1
公开(公告)日：2009-05-12
申请号：US10659820
申请日：2003-09-11
申请人： Kuldipsingh A. Pabla , Charu V. Chaubal , Kenneth Clark , Miha Ahronovitz , Juan C. Soto , Wolfgang G. Gentzsch , Gregory Shirin
发明人： Kuldipsingh A. Pabla , Charu V. Chaubal , Kenneth Clark , Miha Ahronovitz , Juan C. Soto , Wolfgang G. Gentzsch , Gregory Shirin
IPC分类号： G06F15/173 , G06F15/16 , G06F15/177
CPC分类号： G06F9/5072
摘要： An autonomic grid computing mechanism. In embodiments, peer-to-peer platform protocols may be integrated with a grid computing system. Embodiments may use peer-to-peer platform protocols as the transport for the grid computing system. Embodiments may provide one or more of, but not limited to, the following capabilities to grid computing systems: self-deployment and self-configuration, self-updating, self-healing, node removal, master node backup, monitoring, administration, load balancing, grid brokering, decentralized grid, and multi-grid support. Peer-to-peer platform protocols may be used to automatically configure compute nodes. When a node comes up, the node searches for a master node using the peer-to-peer platform. When the node finds a master node, it provides node information to the master node using the peer-to-peer platform. The master node may send the node grid configuration information using the peer-to-peer platform and the node may self-configure as a compute node.
摘要翻译：自主网格计算机制。在实施例中，对等平台协议可以与网格计算系统集成。实施例可以使用对等平台协议作为网格计算系统的传输。实施例可以向网格计算系统提供以下能力中的一个或多个但不限于：自我部署和自配置，自我更新，自我修复，节点移除，主节点备份，监视，管理，负载平衡，网格代理，分散网格和多网格支持。对等平台协议可用于自动配置计算节点。当节点出现时，节点使用对等平台搜索主节点。当节点找到主节点时，它使用对等平台向主节点提供节点信息。主节点可以使用对等平台发送节点网格配置信息，并且节点可以自配置为计算节点。

10. 发明申请

US20070154322A1 PUMPING SYSTEM WITH TWO WAY COMMUNICATION 有权
标题翻译：具有两路通信的抽水系统
公开(公告)号：US20070154322A1
公开(公告)日：2007-07-05
申请号：US11608860
申请日：2006-12-11
申请人： Robert Stiles , Lars Berthelsen , Ronald Robol , Christopher Yahnker , Daniel Hruby , Kevin Murphy , Edward Brown , David MacCallum , Dennis Dunn , Kenneth Clark , Einar Kjartan Runarsson , Alberto Morando
发明人： Robert Stiles , Lars Berthelsen , Ronald Robol , Christopher Yahnker , Daniel Hruby , Kevin Murphy , Edward Brown , David MacCallum , Dennis Dunn , Kenneth Clark , Einar Kjartan Runarsson , Alberto Morando
IPC分类号： F04B49/06
CPC分类号： F04B49/20 , E04H4/1245 , F04B49/06 , F04D13/06 , F04D15/0066 , F04D27/004 , Y10T29/49817
摘要： A pumping system for moving water of a swimming pool includes a water pump, a variable speed motor, and an arrangement for controlling the variable speed motor. The pumping system further includes an auxiliary device operably connected to the arrangement for controlling, and an arrangement for providing two-way communication between the arrangement for controlling and the auxiliary device. The arrangement for controlling is capable of receiving a parameter from the auxiliary device through the arrangement for providing two-way communication. In one example, the arrangement for controlling is capable of independently controlling the variable speed motor without receipt of a parameter from the auxiliary device. In addition or alternatively, the arrangement for controlling is operable to selectively alter operation of the motor based upon the parameter. In addition or alternatively, the arrangement for controlling is configured to optimize a power consumption of the variable speed motor over time based upon the parameters received. A method for controlling the pumping system is also provided.
摘要翻译：用于移动游泳池的水的泵送系统包括水泵，变速电动机和用于控制变速电动机的装置。泵送系统还包括可操作地连接到用于控制的装置的辅助装置和用于在用于控制的装置和辅助装置之间提供双向连通的装置。用于控制的装置能够通过用于提供双向通信的装置从辅助装置接收参数。在一个示例中，用于控制的装置能够独立地控制变速马达而不从辅助装置接收到参数。另外或替代地，用于控制的装置可操作以基于参数选择性地改变电动机的操作。另外或替代地，用于控制的装置被配置成基于所接收的参数来优化可变速电动机随时间的功率消耗。还提供了一种用于控制泵送系统的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式